Alzheimer's Drug Discovery Foundation

September 30, 2018

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

September 28, 2018

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

September 27, 2018

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

September 26, 2018

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

September 25, 2018

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

September 24, 2018

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

September 21, 2018

For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.

September 20, 2018

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

September 19, 2018

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

September 18, 2018

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.